Other substances

Atazanavir

A human immunodeficiency virus protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

General information

Atazanavir is a retroviral protease inhibitor. It is used for prevention and treatment of human immunodeficiency virus (HIV-1) infection and the acquired immunodeficiency syndrome (AIDS) (LiverTox).

Atazanavir on DrugBank
Atazanavir on PubChem
Atazanavir on Wikipedia

Marketed as

ATAZANAVIR SULFATE; REYATAZ (ATAZANAVIR SULFATE)

CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model Preprint In silico	in silico			Feb/02/2020
Discovering drugs to treat coronavirus disease 2019 (COVID-19).	in silico			Feb/22/2020
Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production Preprint	VERO E6 cell cultures		alone or in combination with ritonavir	Apr/06/2020
Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme 3CLpro Small molecule In silico	in silico	3.82	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Jul/17/2020
In Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins Spike protein 3CLpro In silico	in silico	4.07	Predicted to inhibit the SARS-CoV-2 3C-like protease.	Sep/07/2020
Potential protease inhibitors and their combinations to block SARS-CoV-2 3CLpro TMPRSS2 Cathepsin B Cathepsin L Small molecule In silico	in silico	3.22	Predicted to inhibit the host's cathepsins B and L.	Sep/14/2020

AI-suggested references

Link	Publication date
Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?	Nov/30/2021
State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2	Dec/06/2021
Identification of bioactive molecules from tea plant as SARS-CoV-2 main protease inhibitors	Nov/05/2021
Influence of traditional Chinese medicines on the in vivo metabolism of lopinavir/ritonavir based on UHPLC-MS/MS analysis.	Jun/25/2021
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients	Jul/28/2021
Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir.	Aug/28/2020
Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease	Apr/01/2022
Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo	Dec/24/2021
Interferon beta-1b in treatment of severe COVID-19: A randomized clinical trial.	Aug/24/2020
Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production	Sep/21/2020
Virtual screening of plant-derived compounds against SARS-CoV-2 viral proteins using computational tools.	Mar/17/2021
Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2's main protease.	Nov/26/2020
Computational Evaluation of the Inhibition Efficacies of HIV Antivirals on SARS-CoV-2 (COVID-19) Protease and Identification of 3D Pharmacophore and Hit Compounds.	Sep/21/2020
An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).	Nov/23/2021
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model	Feb/16/2021
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics	Jun/14/2020
Tiotropium Is Predicted to Be a Promising Drug for COVID-19 Through Transcriptome-Based Comprehensive Molecular Pathway Analysis	Jul/20/2020
Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.	Mar/15/2021
In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling	Feb/18/2021
A Randomized Clinical Trial of the Efficacy and Safety of Interferon beta-1a in Treatment of Severe COVID-19	Sep/18/2020
DFT investigation of atazanavir as potential inhibitor for 2019-nCoV coronavirus M protease.	Oct/17/2020
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients	Feb/09/2021
Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs	Mar/23/2022
In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel:A Drug Antitarget	May/04/2021
Comparison of the Efficacy and Safety of Atazanavir/Ritonavir Plus Hydroxychloroquine with Lopinavir/Ritonavir Plus Hydroxychloroquine in Patients with Moderate COVID-19, A Randomized, Double-blind Clinical Trial	Feb/24/2022
A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition	Jan/28/2022

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04459286	The Nitazoxanide Plus Atazanavir for COVID-19 Study	Terminated	Phase 2	Oct/09/2020	May/02/2021
Alternative id - NACOVID Interventions - Drug: Nitazoxanide and atazanavir/ritonavir\|Other: Standard of Care Study type - Interventional Study results - No Results Available Locations - Olabisi Onabanjo University Teaching Hospital, Sagamu, Ogun State, Nigeria\|Infectious Disease Hospital, Olodo, Ibadan, Oyo State, Nigeria Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Single (Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 57 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - Time to clinical improvement\|Time to SARS-CoV-2 negativity\|Difference in SARS-CoV-2 AUC\|Time to symptoms resolution\|Clinical status as assessed with the seven-category ordinal scale on days 7 and 14\|Duration of hospitalization in survivors\|Day 28 mortality\|Time from treatment initiation to death\|Proportion with viral RNA detection over time
NCT04468087	Antiviral Agents Against COVID-19 Infection	Active, not recruiting	Phase 2\|Phase 3	Feb/15/2021	Dec/31/2022
Alternative id - REVOLUTIOn Interventions - Drug: Atazanavir\|Drug: Daclatasvir 60 mg\|Drug: Sofusbuvir + Daclastavir 60 mg\|Drug: Placebo Atazanavir\|Drug: Placebo Daclatasvir 60 mg\|Drug: Placebo Sofusbuvir + Daclatasvir 60 mg Study type - Interventional Study results - No Results Available Locations - Hospital do Coracao, Sao Paulo, SP, Brazil Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 256 Age - 18 Years to 90 Years (Adult, Older Adult) Outcome measures - Phase II first step: Change in the slope of SARS-COV 2 viral load\|Phase II second step: Change in the slope of SARS-COV 2 viral load\|Phase III: Number of free days from respiratory support
NCT04452565	NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection	Recruiting	Phase 2\|Phase 3	Jun/15/2022	Dec/15/2023
Alternative id - NATADEX Interventions - Drug: Drug: NA-831\|Combination Product: NA-831 and Atazanavir\|Combination Product: NA-831and Dexamethasone\|Combination Product: Atazanavir and Dexamethasone Study type - Interventional Study results - No Results Available Locations - Coronavirus Research Institute- Testing Site, Los Angeles, California, United States\|Coronavirus Research Institute, Orange, California, United States\|Coronavirus Research Institute-Testing Site, Palo Alto, California, United States\|Coronavirus Research Institute-Testing Site, Sacramento, California, United States\|Coronavirus Research Institute-Testing Site, San Diego, California, United States\|Coronavirus Research Testing Site, San Francisco, California, United States\|Coronavirus Research Institute-Testing Site, Sunnyvale, California, United States\|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States\|Coronavirus Research Institute-Testing Site, Washington, District of Columbia, United States\|Coronavirus Research Institute-Testing Site, Fort Lauderdale, Florida, United States\|Coronavirus Research Institute-Testing Site, Tampa, Florida, United States\|Coronavirus Research Institute- Testing Site, Chicago, Illinois, United States\|Coronavirus Research Institute-Testing Site, Naperville, Illinois, United States\|Coronavirus Research Institute-Testing Site, Baltimore, Maryland, United States\|Coronavirus Research Institute-Testing Site, Bethesda, Maryland, United States\|Coronavirus Research Institute-Testing Site, Boston, Massachusetts, United States\|Coronavirus Research Institute-Testing Site, Worcester, Massachusetts, United States\|Coronavirus Research Institute-Testing Site, Ann Arbor, Michigan, United States\|Coronavirus Research Institute-Testing Site, Detroit, Michigan, United States\|Coronavirus Research Institute-Testing Site, Newark, New Jersey, United States\|Coronavirus Research Institute-Testing Site-, Bronx, New York, United States\|Coronavirus Research Institute-Testing Site, New York, New York, United States\|Coronavirus Research Institute- Testing Site, Rochester, New York, United States\|Coronavirus Research Institute-Testing Site, Durham, North Carolina, United States\|Coronavirus Research Institute-Testing Site, Philadelphia, Pennsylvania, United States\|Coronavirus Research Institute- Testing Site, Fort Sam Houston, Texas, United States\|Coronavirus Research Institute-Testing Site, Galveston, Texas, United States\|Coronavirus Research Institute-Testing Site, Houston, Texas, United States\|Coronavirus Research Institute-Testing Site, Kirkland, Washington, United States\|Coronavirus Research Institute-Testing Site, Seattle, Washington, United States\|Coronavirus Research Institute-Testing Site, Tacoma, Washington, United States Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Prevention Enrollment - 525 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - 1. Time (Hours) to recovery\|Time fever resolution

Export (.csv)